'False affidavit' alleged to help AstraZeneca through holes in Indian procurement
This article was originally published in Scrip
Executive Summary
AstraZeneca has found itself under scrutiny in India over allegations of supplying the injectable antibiotic meropenem at inflated prices to the Delhi government, but the case also puts the spotlight on, what some experts say, is a flawed procurement system for medicines in India.